SHANGHAI – Alphamab Oncology Co. Ltd. now has more than $100 million in its coffers to push its four top antibody candidates through the clinic in China, the U.S., Japan and Australia for the next two years. The series A financing came from venture investors Advantech Capital, PAG, China Venture Capital Fund, Orbimed, Heritage Provider Network and Janchor Partners.